Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position
Chinese Patent Approved Covering HT-KIT Technology Designed to Induce Cancer Cell Apoptosis, Expanding Protection in One of the World’s Largest Oncology Markets Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapeutics, today announced that the China National Intellectual Property Administration has approved issuance of a key patent covering the Company’s […]